Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9558
Title: Effect of neutral endopeptidase inhibitor in rats with congestive heart failure.
Austin Authors: Murohara, Y;Johnston, Colin I
Affiliation: Department of Medicine, Austin Hospital, University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: 1-May-1992
Publication information: Clinical and Experimental Pharmacology & Physiology; 19(5): 380-3
Abstract: 1. The acute hormonal, renal and haemodynamic effects of SCH 39370, a new neutral endopeptidase (NEP) inhibitor, were evaluated in rats with congestive heart failure (CHF) produced by coronary ligation. 2. Left ventricular systolic pressure and left ventricular end diastolic pressure were significantly decreased by SCH 39370 treatment. 3. SCH 39370 improved cardiac function by increasing cardiac index and decreasing total peripheral resistance. 4. SCH 39370 induced a transient but significant diuresis and natriuresis. 5. These effects were associated with significant increases in urinary atrial natriuretic peptide (ANP) and cyclic GMP excretion, but not with an increase in plasma ANP levels. 6. The results suggest that NEP inhibition may be a new therapeutic method for treating CHF possibly by potentiating the biological activities of endogenous ANP.
Gov't Doc #: 1325886
URI: http://ahro.austin.org.au/austinjspui/handle/1/9558
URL: https://pubmed.ncbi.nlm.nih.gov/1325886
Type: Journal Article
Subjects: Animals
Atrial Natriuretic Factor.urine
Cardiac Output.drug effects
Cyclic GMP.urine
Dipeptides.pharmacology
Female
Heart Failure.drug therapy.enzymology.physiopathology
Hemodynamics.drug effects
Kidney.drug effects
Pharmaceutical Vehicles.pharmacology
Protease Inhibitors.pharmacology
Rats
Rats, Inbred Strains
Vascular Resistance.drug effects
Ventricular Function, Left.drug effects
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Dec 5, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.